alexa Safety Monitoring of Drug Interchangeability

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

2nd Euro Sports Medicine-Fitness and Physiotherapy

Vancouver, Canada

Global Summit on Pediatrics

Madrid, Spain
Safety Monitoring of Drug Interchangeability

When an innovative (brand-name) drug is going off patent protection, the innovative drug companies and/or generic drug companies may file an abbreviated new drug application (ANDA) for generic approval through the conduct of a bioequivalence study. Bioequivalence testing for generic approval is based on the Fundamental Bioequivalence Assumption that when two drug products have similar drug absorption profiles (or equivalent in average bioavailability), it is assumed that they will reach similar therapeutic effects or they are therapeutic equivalent. Two drug products are claimed to be bioequivalent if the 90% confidence interval for the geometric mean ratio (GMR) is totally within the bioequivalent limits of (80.00%, 125.00%) based on log-transformed data. For an approved generic drug product, the United States Food and Drug Administration (FDA) indicate that it can be used as a substitute of the brand-name drug.

Submit your manuscripts at
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger